Drugmaker Gilead is seeking approval for its HIV medication, lenacapavir (Sunlenca), as a preventive measure. The drug has shown 100% effectiveness in women and near-perfect results in men. Gilead will make cheaper generic versions available in 120 poor countries, but its exclusion from Latin America could hinder progress.
The drug lenacapavir, sold as Sunlenca to treat HIV, shows promise in preventing HIV infections, with 100% effectiveness in women and near-perfect results in men. Gilead plans to seek approval for its use as a preventative measure. The company will allow generic versions to be sold in 120 poor countries, mostly in Africa, Southeast Asia, and the Caribbean, but has excluded Latin America, raising concerns.
UNAIDS credits Gilead for its development but stresses the importance of its use in at-risk regions. The drug could significantly aid marginalized communities who fear seeking regular medical care
HIV Infections Prevention Gilead Lenacapavir Sunlenca AIDS UNAIDS Generic Drugs
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Gilead's HIV Prevention Drug Shows Promise, But Global Access Remains In QuestionGilead Sciences Inc. aims to use lenacapavir as an HIV prevention tool, showing significant efficacy in studies. The drug's availability in 120 poor countries is welcomed, but its exclusion from most of Latin America raises concerns.
Read more »
Gilead's HIV Prevention Shot Shows Near 100% Effectiveness, But Accessibility Concerns PersistGilead Sciences plans to seek approval for its HIV prevention drug, with a study indicating near 100% effectiveness in preventing HIV infections. The drugmaker will allow generic versions to be sold in 120 low-income countries, but has excluded most of Latin America, sparking concerns over missed prevention opportunities.
Read more »
Clinical trial reveals twice-yearly injection to be 96% effective in HIV preventionRecent results from a recent clinical trial indicate that a twice-yearly injection of Lenacapavir offers an overall 96% reduced risk of acquiring HIV. This makes Lenacapavir significantly more effective than the standard daily oral PrEP (pre-exposure prophylaxis).
Read more »
How Gilead Is Driving Global Health Equity And InnovationChase Feiger, M.D. is the co-founder & CEO of Ostro, a company building AI solutions for large, mid-size, and small life science companies. Previously, Feiger co-founded Parsable and worked in venture capital, investing in 20+ companies.
Read more »
A twice-yearly shot could help end AIDS. But will it get to everyone who needs it?The drug is already sold to treat HIV infections and Gilead plans to seek approval soon to use it to guard against infections.
Read more »
Opinion: Living with HIV/AIDS means caring for the mind, body, and spiritThirty-six years ago, the World Health Organization declared Dec. 1 as World AIDS Day, creating an international day of awareness for those living with HIV and AIDS. For us, every Dec. 1 is a call …
Read more »